The Omes of Inflammatory Bowel Disease–A Primer for Clinicians

ABSTRACT Recent advances in high-throughput laboratory technologies and bioinformatics tools are redefining how we view inflammatory bowel disease (IBD). Instead of two diseases we now see a diverse set of molecular subtypes. Large scale investigation of the genome, exome, transcriptome, proteome, metabolome, microbiome, and epigenome are providing transformative insights into the pathophysiology of IBD, with the promise of accurately predicting prognosis and targeting therapy. Understanding these tools and their application is crucial to navigating the molecular era of IBD. This review aims to help the IBD clinician understand, appreciate and eventually incorporate this coming paradigm shift in order to improve the care of children with IBD. Address correspondence and reprint requests to Neal S. LeLeiko, MD PhD, Department of Pediatrics, Hasbro Children's Hospital/Rhode Island Hospital, MPH Rm 134, 593 Eddy Street, Providence RI 02903 (e-mail: Neal_LeLeiko@brown.edu;nleleiko@gmail.com). Received 31 July, 2017 Accepted 13 November, 2017 Disclosure of funding: There was no funding for the preparation of this manuscript. © 2017 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2k7Pb2y
via IFTTT